VolitionRx Announces Expansion of Nu.Q® Vet Cancer Test Agreement with Fujifilm Vet Systems
Henderson, NV, March 13, 2025 – VolitionRx Limited, a leading epigenetics company, is thrilled to announce the expansion of its existing supply agreement with Fujifilm Vet Systems Co. Ltd, a prominent veterinary diagnostic company in Japan. This new agreement will allow Fujifilm Vet Systems to offer Volition’s Nu.Q® Vet Cancer Test using the Immunodiagnostic Systems (IDS) i10® automated analyzer platform, featuring the chemiluminescent immunoassay (ChLIA) version of the test.
Background
For those unfamiliar, VolitionRx is a multi-national epigenetics company focused on developing simple, easy-to-use, cost-effective blood tests for various diseases. Their Nu.Q® technology identifies and measures the presence of specific nucleosomes in the blood, which can indicate the presence of various diseases, including cancer. Fujifilm Vet Systems, on the other hand, is a subsidiary of Fujifilm Corporation and a leading provider of veterinary diagnostic services and solutions in Japan.
The Expanded Agreement
The original agreement, which began in 2019, granted Fujifilm Vet Systems the rights to distribute Volition’s Nu.Q® Vet Cancer Test in Japan using their existing platform. With the expansion, Fujifilm Vet Systems will now be able to offer the ChLIA version of the test, which is known for its high sensitivity and specificity. This new version of the test uses a different detection method, making it a valuable addition to their current offerings.
Impact on the Consumer
This expansion of the agreement is great news for pet owners in Japan. The Nu.Q® Vet Cancer Test, which can detect various types of cancer in pets, will now be available via the popular IDS i10® automated analyzer platform. This means that veterinarians will be able to process the test results more efficiently, providing pet owners with faster and more accurate results. Additionally, the ChLIA version of the test offers improved sensitivity, potentially leading to earlier cancer detection and better treatment outcomes for pets.
Impact on the World
Beyond Japan, this agreement represents a significant step forward for VolitionRx in expanding the reach of their Nu.Q® Vet Cancer Test. By partnering with Fujifilm Vet Systems, a leading player in the Japanese veterinary diagnostics market, they are able to tap into a large and growing market. Furthermore, the success of this partnership could lead to similar agreements with other diagnostic companies, allowing Volition’s Nu.Q® Vet Cancer Test to be offered on additional platforms and in more countries, ultimately benefiting pet owners worldwide.
Conclusion
In summary, VolitionRx’s expansion of its Nu.Q® Vet Cancer Test agreement with Fujifilm Vet Systems is a win-win situation for both companies and pet owners in Japan. The addition of the ChLIA version of the test via the IDS i10® automated analyzer platform will provide faster and more accurate results, while also potentially leading to earlier cancer detection. Furthermore, this partnership could pave the way for VolitionRx to expand the reach of their Nu.Q® Vet Cancer Test in other markets, ultimately benefiting pet owners worldwide.
- VolitionRx expands agreement with Fujifilm Vet Systems in Japan
- New agreement includes ChLIA version of Nu.Q® Vet Cancer Test on IDS i10® platform
- Improved sensitivity and efficiency for pet cancer detection
- Potential for further global expansion of Nu.Q® Vet Cancer Test
